Evidence map›Paper›PMID 41879717›Full record

ArticleAddiction biology2026

Engaging Gut-to-Brain Signalling to Treat Alcohol Use Disorder.

Paula L Hoffman, Giordano de Guglielmo, Valentina Vengeliene, Wolfgang Kunze, Christina L Lebonville, Jerome D Swinny, Amanda J Roberts, Olivier George, Karen-Anne McVey Neufeld, Alexandra Dunbar and 6 more

Abstract read
In one paragraph

Article in Addiction biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Paula L HoffmanLohocla Research Corporation, Aurora, Colorado, USA.ORCID 0000-0002-6443-4225
Giordano de GuglielmoDepartment of Psychiatry, School of Medicine, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-4782-7430
Valentina VengelieneInstitute for Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany.ORCID 0000-0002-6182-2564
Wolfgang KunzeThe Brain-Body Institute, Gut, Brain & Aging Laboratory, McMaster University, Hamilton, Ontario, Canada.
Christina L LebonvilleDepartment of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Jerome D SwinnySchool of Medicine, Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, UK.ORCID 0000-0002-8194-5481
Amanda J RobertsAnimal Models Core Facility, Scripps Research, La Jolla, California, USA.
Olivier GeorgeDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Karen-Anne McVey NeufeldThe Brain-Body Institute, Gut, Brain & Aging Laboratory, McMaster University, Hamilton, Ontario, Canada.
Alexandra DunbarLohocla Research Corporation, Aurora, Colorado, USA.
Laura M SabaDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Ruolin MaSchool of Medicine, Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
Leandro F VendruscoloStress and Addiction Neuroscience Unit, National Institute on Drug Abuse Intramural Research Program, NIH, Baltimore, Maryland, USA.
Howard C BeckerDepartment of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID 0000-0001-8042-6957
Rainer SpanagelInstitute for Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany.ORCID 0000-0003-2151-4521
Boris TabakoffLohocla Research Corporation, Aurora, Colorado, USA.ORCID 0000-0001-5132-5030

Funding

TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Lisa M McTeague · 1996 to 2026
$46.8M
Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2003 to 2026
$46.3M
The Impact of Stress and Craving on Return to Postpartum Cannabis UseU54DA016511 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI AIMEE L MCRAE-CLARK · 2018 to 2026
$15.9M
Ethanol Dependence &Stress Effects on Ethanol DrinkingU01AA014095 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HOWARD C. BECKER · 2003 to 2026
$9.0M
Nezavist a Novel Molecule for Treatment of Alcohol Use DisorderU44AA024905 · NIAAA · LOHOCLA RESEARCH CORPORATION · PI TABAKOFF, BORIS · 2015 to 2021
$7.7M
Nezavist a Novel Molecule for Treatment of Alcohol Use DisorderR44AA024905 · NIAAA · LOHOCLA RESEARCH CORPORATION · PI TABAKOFF, BORIS · 2022 to 2025
$5.1M
Alcohol Vapor Self-Administration in RatsR01AA022977 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Olivier George · 2014 to 2026
$5.1M
Role of Oxytocin in a Mouse Model of PTSD-AUD ComorbidityR01AA026536 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BECKER, HOWARD C. · 2017 to 2021
$1.9M
Natural Sciences and Engineering Research Council of Canada (NSERC)NIAAA NIH HHS P50 AA010761NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R01 AA022977NIAAA NIH HHS R01 AA026536NIAAA NIH HHS R44 AA024905NIAAA NIH HHS U01 AA014095NIAAA NIH HHS U44 AA024905NIDA NIH HHS U54 DA016511NIH HHS P50AA010761[HCB]NIH HHS P60AA006420 [OG, AJR]NIH HHS R01AA022977[OG]NIH HHS R01AA026536 [HCB]NIH HHS R44AA024905 [BT,PLH]NIH HHS U01AA014095 [HCB]NIH HHS U44AA024905 [BT,PLH]NIH HHS U54DA016511 [CLL]NIH HHS Z1A-DA000644 [LFV]
6 · The paper itself

Abstract

According to the 2023 National Survey on Drug Use and Health (NSDUH), 28.9 million people ages 12 and older in the United States had alcohol use disorder (AUD) in the past year. Although chronic alcohol use contributes to numerous health disorders as well as being an economic burden, there are few medications approved for treatment of AUD, and these medications are not uniformly effective and are not widely used. We now describe studies of a small molecule, novel chemical entity called Nezavist, which shows promise as a medication to treat AUD and possibly other addictive disorders. Nezavist acts as a positive allosteric modulator at a novel site on the GABA

Indexed as

AlcoholismBrainGastrointestinal TractAnimalsHumansReceptors, GABA-ASignal TransductionSolitary NucleusVagus NerveReceptors, GABA-AAUDgut–brain signallinghippocampal inflammatory mediatorsNezavistNTS activationperipheral inflammationvagal activation

Identifiers

PMID41879717
PMCPMC13093268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.